<DOC>
	<DOCNO>NCT00940225</DOCNO>
	<brief_summary>The purpose study determine whether XL184 demonstrate anti-tumor activity select tumor type randomize discontinuation trial ( RDT ) design . Subjects respond study drug 12 week open-label XL184 administration continue take XL184 . Subjects clearly progressing discontinue study treatment subject demonstrate stable disease randomize either XL184 placebo . For individual patient , disease progression observe , blind broken subject randomize placebo offer option receive open-label XL184 . Subjects progress take XL184 discontinue study treatment . Emerging data may support enrollment open-label , non-randomized expansion cohort ( NRE ) . There NRE cohort prostate ovarian cancer .</brief_summary>
	<brief_title>Study Cabozantinib ( XL184 ) Adults With Advanced Malignancies</brief_title>
	<detailed_description />
	<criteria>The subject cytologically histologically radiologically confirm , advance , recurrent , metastatic solid tumor nine type list : Pancreatic Cancer CastrationResistant Prostate Cancer ( CRPC ) Hepatocellular Carcinoma ( HCC ) Gastric Gastroesophageal Junction Cancer Melanoma Small Cell Lung Cancer ( SCLC ) Ovarian cancer , primary peritoneal fallopian tube carcinoma Breast cancer one follow subtypes : estrogen receptor positive breast cancer , estrogen receptor/progesterone receptor/HER2negative ( triplenegative ) , inflammatory ( regardless receptor status ) disease histology NonSmall Cell Lung Cancer ( NSCLC ) Certain requirement prior therapy may apply The subject document progressive disease screen Subjects tumor type CRPC must least one lesion within previously irradiate field measurable CT MRI scan The subject recover baseline CTCAE ≤ Grade 1 toxicity relate prior treatment ( exception apply ) The subject ≥ 18 year old day consent Tissue sample archival fresh tissue , tissue block subject 's tumor The subject Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 The subject adequate organ function The subject capable understanding comply protocol requirement sign informed consent document Sexually active fertile subject ( male female ) , partner , must agree use medically accept method contraception course study 3 month last dose study drug ( ) Female subject childbearing potential must negative pregnancy test screen The subject experience clinicallysignificant hematemesis hemoptysis &gt; 0.5 teaspoon red blood , sign indicative pulmonary hemorrhage within 3 month first dose study treatment The subject cavitating pulmonary lesion ( ) pulmonary lesion abut encase major blood vessel Certain restriction prior treatment apply The subject receive drug use control loss bone mass within 4 week prior first dose study treatment The subject know symptomatic uncontrolled brain metastasis epidural disease The subject prothrombin time/International Normalized Ratio ( PT/INR ) partial thromboplastin time ( PTT ) test result ( 1.3x ) laboratory upper limit normal The subject correct QT interval ( QTcF ) &gt; 500 m screen The subject require concomitant treatment , therapeutic dos , anticoagulant warfarin Coumadinrelated agent , heparin , thrombin FXa inhibitor , antiplatelet agent ( lowdose aspirin ( ≤81 mg/day ) , lowdose warfarin ( ≤1mg/day , prophylactic low molecular weight heparin ( LMWH ) permit ) The subject uncontrolled , significant intercurrent illness The subject unable swallow capsule The subject pregnant breastfeed The subject previouslyidentified allergy hypersensitivity component study treatment formulation The subject unable unwilling abide study protocol cooperate fully investigator designee The subject another diagnosis malignancy require systemic treatment within last two year , unless nonmelanoma skin cancer , insitu carcinoma cervix , superficial bladder cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Stomach Gastroesophageal Junction Carcinoma</keyword>
	<keyword>Hepatocellular Carcinoma ( HCC )</keyword>
	<keyword>Small Cell Lung Cancer ( SCLC )</keyword>
	<keyword>Non-Small Cell Lung Cancer ( NSCLC )</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Prostate Cancer</keyword>
</DOC>